Endometriosis may be a definitive risk factor for ovarian cancer, the most fatal gynecological cancer. The ability of endometriosis to transform into malignancy, first described by Dr. Sampson in 1925, is considered a rare occurrence, affecting approximately 1% of ovarian endometriomas. Recently we conducted a retrospective study regarding the malignant transformation of endometriosis in Japanese women. Many studies have reported a consistent correlation between endometriosis and ovarian cancer according to histological subtypes. However, the existing epidemiological evidence linking this association is insufficient to define the role of endometriosis as a cause of ovarian cancer and to influence changes to current clinical practice. Prospective cohort studies are therefore needed to clarify this issue. Additionally, the results of many molecular studies are conflicting, and earlier studies showing the molecular aberrations involved in genomic instability and mutation that enable malignant transformation have not been replicated in later studies. Careful long-term observation of a patient with endometrioma is required to detect possible subsequent incidence of malignant transformation. More importantly, a precise strategy should be set up for better prevention, early detection, specific diagnosis and treatment targeting molecular pathogenesis to understand the mechanisms of endometriosis-associated ovarian cancer. Clinicians need to be aware of the increased ovarian cancer risk in women with endometriosis.
Introduction
Endometriosis occurs in 10% of women of reproductive age. 1 In recent years, the rate in Japan has increased as a result of late marriage and delayed childbearing. Although the definite pathogenesis of endometriosis is still unknown, many theories have been proposed, including retrograde menstruation, coelomic metaplasia, embryonic cell rest, lymphovascular metastasis and stem cell. 2 Recently, it is reported that both endometrium-derived and bone marrow-derived stem cells can migrate to ectopic sites and contribute to the development of endometriosis. 2, 3 The pathogenesis of endometriosis is multi-factorial, including roles of genetics, hormonal factors, environmental factors and the immune system. [4] [5] [6] [7] Epidemiologic, histopathologic and molecular data suggest that endometriosis has malignant potential. 8 To support that possibility, the likely etiological association between endometriosis and ovarian cancer has been repeatedly studied. It is hypothesized that endometriosis-associated malignancies typically arise from ovarian endometrioma. The prevalence of ovarian cancer in women with endometriosis is higher than that of sporadic ovarian cancer in the general population. In addition, endometriosis and ovarian cancer have common predisposing factors, such as early menarche and late menopause, short intervals between menses and nulliparity. Conversely, increasing parity, use of oral contraceptives, tubal ligation and hysterectomy are also inversely associated with both endometriosis and ovarian cancer. 8 Of note, there is evidence to indicate that tubal ligation is strongly associated with a reduced risk of nonserous types of ovarian cancer, especially, clear-cell (CCC) and endometrioid carcinoma (EC). [9] [10] [11] Epidemiological studies have indicated a correlation of endometriosis specifically with these two histological types of ovarian cancer, 12 supporting the theory of retrograde menstruation for the etiopathogenesis of endometriosis.
Nevertheless, prospective studies assessing the relationship between endometriosis and ovarian cancer are still lacking and existing epidemiological evidence is insufficient to change current clinical practice. Furthermore, the exact rate of malignant transformation of endometriosis is unknown as ovarian endometrioma, the most common form of endometriosis accounting for 55% of this disorder, 13 are not always resected and subsequently confirmed by pathological diagnosis. A unique epidemiologic prefecture-wide Shizuoka Cohort Study on Endometriosis and Ovarian Cancer Programme in Japan reported that the risk of ovarian cancer was elevated in patients with a large endometrioma. Approximately 0.72% of patients with ovarian endometrioma subsequently developed ovarian cancer.
14 In another retrospective observational cohort study of 12 193 infertile women in the United States, 13 of 45 women with ovarian cancers had been treated for infertility associated with endometriosis. Patients with endometriosis showed a 2.7-fold excess risk of ovarian cancer compared to those without endometriosis. 15 The detailed characteristics and behavior of the malignant transformation of endometriosis are intriguing, and the impact of therapeutic methods on subsequent cancer development still poorly understood. Almost all studies of the occurrence of malignancies among patients with endometriosis used either self-reporting 16 or the national register. 17, 18 Further studies are needed to understand the mechanism and characteristics of endometriosis-associated ovarian cancer (EAOC). As the first prospective cohort study in the world, the Japan endometriosis malignant transformation study (JEMS) has already started to clarify these issues. In this article, we sought to delineate these issues and present our recent findings.
Etiology and terminology of endometriosis-associated ovarian cancer (EAOC)
Many authors have reported that endometriosis represents an important site of origin of ovarian cancer, especially in CCC and EC subtypes, which are relatively rare histotypes among ovarian cancers. 14, 19, 20 According to the results of a meta-analysis including 7911 women with invasive ovarian cancer conducted to evaluate the association between endometriosis and histological subtypes of ovarian cancer, a history of endometriosis (self-reported) is associated with an increased risk of ovarian cancer, especially among CCC, invasive low grade serous and EC subtypes. 16 In order to consider neoplastic transformation of endometriosis, Sampson and Scott proposed the following criteria: (i) tumor is adjacent to unequivocal foci of endometriosis, (ii) absence of any other primary tumor, (iii) microscopic features are within a spectrum of well-recognized neoplasms originating from endometriosis, and (iv) a transition from neoplastic epithelium (or stromal component) to endometriosis. 21, 22 Although a small subset of ovarian cancers fulfill these stringent criteria, pathological evidence of malignant transformation and the precise incidence of this phenomenon are still difficult to ascertain. Indeed, cases with all of the above criteria have rarely been found because of sampling techniques and possible destruction of benign tissue by tumor invasion.
The source population of ovarian cancer progenitors has become a matter of controversy. It is generally accepted that epithelial ovarian cancer originates from the ovarian surface epithelium (OSE). It has been argued that the OSE (mesothelium) undergoes a metaplastic transformation, resulting in carcinoma. Ovarian endometrioma may also be derived from a metaplastic process from the mesothelial lining of inclusion cysts consisting of OSEs, although its pathogenesis is still controversial. Thus, OSEs retaining the properties of pluripotent cells can be represented as a common source of endometriomas and EAOC.
Recently, Kuhn et al. proposed a new theory of ovarian carcinogenesis, that the fallopian tube epithelium implants on the ovary give rise to both high-grade and low-grade serous carcinomas, and that endometrial tissue implants on the ovary and produces endometriosis, which can then undergo malignant transformation into EC and CCC. 23 In addition, Shih et al. proposed the term, endometriosis-related neoplasms (ERON), the most alarming complication of endometriosis, which is defined as a neoplastic condition arising from endometriosis through clonal expansion of its constituents, including epithelial or stromal components. EC, CCC, seromucinous borderline tumor, squamous cell carcinoma, Mullerian adenosarcoma and endometrioid stromal sarcoma are collectively known as ERONs. 24 
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Clinical characteristics of patients with ovarian cancer arising from endometrioma in Japan
We previously investigated the clinical features of patients with malignant transformation of ovarian endometrioma in Japan. 25 Thirty-three patients diagnosed with ovarian cancer presumably arising from endometriomas, from 2008 to 2010, were enrolled. The average age of patients was 47.7 years (range 31-74); 75.7% were premenopausal at the time of ovarian cancer diagnosis. Twenty-two patients (69.7%) had regular menstrual cycles, and only nine patients (27.2%) needed medication for dysmenorrhea. The noteworthy finding is that ovarian cancer developed in the ipsilateral ovary of six out of 33 patients after cystectomy for endometrioma.
The mean largest diameter of ovarian endometrioma was 8.1 cm (range 2.0-20.0 cm) and the mean preoperative cancer antigen (CA)125 value was 110.8 U/ml (range 10.0-642.0 U/ml). These parameters did not significantly correlate (r = 0.359, P = 0.165). In our study, 45.5% of 33 patients exhibited a more than two-fold elevation of CA125 value; however, in 42.4%, the CA125 value was under 35 U/ml even after malignant transformation, suggesting that CA125 is not a critical marker in diagnosing malignant transformation of endometriosis.
The postoperative International Federation of Gynecology and Obstetrics stage of nearly 85% of patients was stage I (Ia 15.2% and Ic 69.6%), and major histotypes were CCC in 23 cases (69.7%) and EC in eight cases (24.2%). The maximum diameter of the endometrioma in the 30 patients (90.9%) increased more than two-fold in six months when the malignant transformation was diagnosed. As several reports have shown, CCC is frequently diagnosed at an early stage; 21 patients in 23 cases of CCC in our study were diagnosed with stage I. Two cases transformed from less than 4 cm endometriomas with the small mural nodule. Even when the endometrioma is small, an examination for the presence of mural nodules is crucial to diagnose malignant transformation. To detect malignant transformation early and precisely, the clinician should determine the existence of a mural nodule and assess the rapid growth of endometrioma.
Nineteen patients diagnosed with ovarian cancer after conservative surgery (i.e. cystectomy, aspiration of cyst fluid or electrocautery of cyst wall) and/or hormonal treatment (gonadotropin-releasing hormone agonist, oral contraceptive [OC], etc.) for endometriomas were reported. The other 14 patients did not receive any treatment before surgery for ovarian cancer. More than 70% of 33 patients were diagnosed with malignant transformation within 10 years of follow-up of their endometriomas. The potential of invasive epithelial malignancies arising in atypical endometriosis has been shown. 19, 26 In this study, the histological findings of atypical endometriosis were observed in approximately 60% of patients.
Clinical management for ovarian endometrioma
In addition to our report, two studies investigating the risk of ovarian cancer in women with endometriosis and warned that endometrioma excision does not prevent the subsequent development of ovarian cancer. 27, 28 The results of our study support this finding. Haraguchi et al. reported that all ovarian cancers in their study samples developed from a recurrent endometrioma. 28 Ovarian cancers can develop after cystectomy of endometrioma and are more likely to arise from recurrent endometrioma. The use of OC is a potentially promising primary prevention strategy for ovarian cancer. The majority of studies that have examined the relationship between combined OC use and ovarian cancer have reported a decreased risk with their use. From the viewpoint of ovarian function, a second surgery for recurrent endometrioma has been considered more harmful to the healthy ovarian tissue, suggesting that indications for surgery for recurrent endometrioma should be considered with caution. Further studies are required to determine whether prevention of endometrioma recurrence using OC or other medications is associated with subsequent ovarian cancer development.
In a retrospective cohort study using the National Swedish Inpatient Register and National Swedish Cancer Register, Melin et al. reported that one-sided oophorectomy, as well as radical extirpation of all visible endometriosis, has a strong protective effect against the subsequent development of ovarian cancer, but cystectomy does not. 29 In other words, oophorectomy effectively reduces the risk of ovarian cancer. Kobayashi et al. reported that patients aged > 45 with a large endometrioma had a higher incidence of malignant transformation. They further defined premenopausal women with an endometrioma 9 cm or more in diameter as a high-risk group and recommended extensive treatment, including surgical resection.
14 Based on these data, we recommend salpingo-oophorectomy for patients > 40 years old who do not desire pregnancy and present with symptomatic endometrioma. In addition, Merin et al. stated that women who had hysterectomy before or at the time of the endometriosis diagnosis did not have an increased the risk of ovarian cancer. 18 Buis et al. evaluated the risk of ovarian cancer in subfertile women diagnosed with endometriosis in a nationwide, historic cohort study consisting of 3657 women with endometriosis and 5247 without evidence of endometriosis. 30 In contrast to previous studies, diagnosis was pathologically confirmed in 78% of endometriosis cases. The Dutch Pathology Database and the Netherlands Cancer Registry were linked to assess the occurrence of ovarian cancer and ovarian borderline tumors in these patients. Women with endometriosis appeared to have an increased risk of ovarian cancer. However, the extent of the risk was lower after excluding information from the pathology database, possibly because the studies depended on self-reported information of endometriosis and nondifferential misclassification bias. The low numbers of ovarian cancer cases and the inclusion of infertility patients only, leading to wide confidence intervals, were limitations of this study.
In addition, as a non-invasive predictive tool to detect malignant changes in endometrioma, the efficacy of three-dimensional power Doppler angiography (3D-PDA) 31 and magnetic resonance relaxometry, have been shown. 32 The abrupt development of endometrioma and mural nodule formation should be assessed carefully to determine the increased risk of malignant transformation and provide special care, such as rigorous follow-up.
The treatment should be personalized based on the patient's age, desire to bear children, family history and type and characteristics of endometriomas. At the time of surgical diagnosis and treatment, consideration of complete resection of pelvic endometriosis, salpingectomy, oophorectomy or hysterectomy should be individualized based on a patient's age, desire for future fertility and preoperative consultation with the patient.
Pathogenesis of EAOC
Current studies have sought to link endometriosis with ovarian cancer through pathways or networks related to inflammation, oxidative stress and hyperestrogenism. 33 Inflammation is considered to be an indicator of endometriosis and local inflammatory reactions within ovarian endometrioma evoke high levels of proinflammatory cytokines (interleukin [IL]-1, IL-6, IL-8, tumor necrosis factor-α, and tumor necrosis factor-β) that play a vital role in angiogenesis, cell proliferation and production of reactive oxygen species. 26, 34, 35 Apoptosis is inhibited and a stressful change of the microenvironment enhances tumor invasion and metastasis, contributing to both the occurrence and progression of neoplastic processes. The influence of inflammation accompanying surgery may also be one of the causes of malignant transformation.
Oxidative stress, local inflammatory reactions, and hyperestrogenism have been identified in the tumorigenesis of EAOC. Abundant free iron content and stress-related factors, including lactose dehydrogenase, lipid peroxidase and 8-hydoroxy-2-deoxyguanosine in the contents of endometrioma are associated with greater oxidative stress and DNA damage. In fact, retrograde menstruation and repetition of hemorrhage in endometrioma induces heme and free iron accumulation, which may play a role in carcinogenesis. In addition, higher aromatase activity and local concentrations of estradiol inside endometriosis stimulates cyclooxygenase-2 and prostaglandin E2 production, which are implicated in tumor progression.
It is generally assumed that benign endometriotic lesions may be caused by the genetic defects that are permissive for malignant transformation. Loss of heterozygosity and mutations of tumor suppressor genes in endometriosis have been documented. This disorder exhibits high genetic instability that is involved in the cell phenotype changes that take place during cancer progression. To understand the precise carcinogenic mechanisms and identify the aberrant expression of biomarkers associated with the malignant transformation of endometrioma, a variety of molecular alterations have been investigated. These include ATrich interactive domain 1A (ARID1A) mutation, loss of BRG1-associated factor 250a (BAF250a), 36 B-cell lymphoma 2 (BCL-2) and P53 alteration, 37 phosphatase and tensin homolog (PTEN) silencing, Kirsten rat sarcoma viral oncogene homolog (K-RAS) mutations, 38 and hepatocyte nuclear factor (HNF)-1β activation. 39 Interesting, a study by Wiegend et al. has identified the critical role of ARID1A mutations that are common to EC and CCC, and showed that 55 (46%) of 119 CCC and 10 (30%) of 33 EC patients had ARID1A mutations. More importantly, in two patients, ARID1A mutations were evident in primary malignant lesions and contiguous atypical endometriosis but not in distant endometriotic lesions. 36 Atypical endometriosis is considered a precursor lesion of malignant change because the presence of either hyperplasia or cytological atypia adjacent to concomitant CCC has been identified. Additionally, a direct continuous transitional area from atypical endometriosis to carcinoma was also noted. Definite atypical endometriosis, as defined by Czernobilsky & Morris and LaGrenade & Silverberg, include abnormal but not malignant epithelial cells, which exhibit large hyperchromatic or pale nuclei with moderate to marked pleomorphism; an increased nuclear/cytoplasmic ratio; and tall, crowded and stratified epithelial cells. 40, 41 In a study by Fukunaga et al., such atypical endometriosis was identified in 18 CCCs and seven ECs. CCC and EC were frequently associated with endometriosis, with 54% and 41.9% respectively. 42 In a study by Ogawa et al. of 37 cases with endometriosis and ovarian carcinomas, 22 cases showed transition from typical endometriosis to atypical endometriosis and 23 cases showed transition from atypical endometriosis to carcinoma. 19 Ballouk et al. also reported that DNA aneuploidy was observed in half of the endometriotic cysts with severe atypia. These results further support the hypothesis of the potential of invasive epithelial malignancies that arose in these atypical endometriotic cysts. 43 Genetic models of peritoneal endometriosis and EC were presented in mice, which revealed that the expression of oncogenic K-ras or conditional Pten deletion in the OSEs induced endometriosis.
Furthermore, a combination of the two mutations in the ovary led to EC. 44 Mutations of phosphoinositide 3-kinase (PI3K)/ Pten and Wnt/β-catenin signaling pathways have also been shown to cooperate in the development of EC in mice. 45 Aberrant expression of fibroblast growth factor receptor-2 (FGFR2) on malignant transformation of ovarian endometriomas
We previously demonstrated that enhancement of fibroblast growth factor receptor-2 (FGFR2) gene expression may be involved in the malignant transformation of endometriosis. 46 Using Gene Chip Array that can analyze the expression levels of over 54 617 transcripts and1 variants, the gene expression levels in three different samples of epithelial cells were determined. Samples were obtained by laser capture microdissection (LCM) as follows: A) ovarian endometrioma, B) matched endometrioma adjacent to CCC, and C) CCC. Firstly, 39 upregulated genes that showed increased expression levels among the following comparisons: A versus B, B versus C and A versus C were verified. The KEGG pathway database classification was then used to decide nine genes (12 probes) involved in the various signaling pathways. FGFR2 expression was two-fold higher in all three different probe sets for all pairs of comparisons (Table 1) . Moreover, it was more intense in CCC compared to epithelial cells in endometrioma. 39, 40 For the first time, we report FGFR2 expression in the epithelial cells of endometrioma and its upregulation in the course of We also showed the data indicating the 17 downregulated genes in all three pairs of comparisons in this microarray analysis. 46 These genes indicated a decreased expression ratio (< two-fold) for A versus B, B versus C and A versus C: CD74 molecule; heat shock protein 1A; inhibitor of DNA binding 2; activated leukocyte cell adhesion molecule; serpin peptidase inhibitor-clade E; suppressor of cytokine signaling 2; growth arrest-specific 1; endothelin receptor type A; amine oxidase, copper-containing 3; class II major histocompatibility complex; monoamine oxidase A; ST3 β-galactoside α-2,3-sialyltransferase; wingless-type mouse mammary tumor virus integration site family; collagen; type V (α2); steroid 5α-reductase 3; and sacroglycan β.
46
In recent years, genetic alterations associated with the malignant transformation of endometriosis have been reported. Using genome expression profiling of CCC samples isolated by LCM, 22 representative activated genes, such as enolase (ENO1), vascular endothelial growth factor (VEGF), placental growth factor (PGF), fms-related tyrosine kinase 1 (FLT1) and hypoxiainducible factor (HIF 1α), were identified. Based on microarray analysis, angiogenesis and glycolysis pathways may be important in the survival and progression of CCC. 47 Role of FGFs and FGFR2 on the malignant transformation of ovarian endometriomas Fibroblast growth factors comprise a family of heparinbinding proteins, which include 22 members that exert signals through four high-affinity tyrosine kinase receptors (FGFR 1-4) . The FGFR2 gene is expressed by alternative splicing in epithelial FGFR2IIIb (encoded by exon 8) or mesenchymal FGFR2IIIc isoforms (utilizing exon 9). In fact, epithelial FGFR2IIIb is unique because it interacts only through the keratinocyte growth factor receptor (KGFR) that binds ligands FGF7 (KGF) and FGF10 with high affinity and is expressed exclusively by epithelial cells. We demonstrated FGFR2IIIb expression in the OSE cells of endometrioma. CCC could thus represent FGFR2IIIb.
We have also shown FGF7 gene expression in human ovarian cells, and that of FGF10 only in the cal/stromal cells of normal ovaries or in endometriotic stromal cells. 42 Other research groups have reported the presence of messenger RNA transcripts for FGF2 in stromal and granulosa cells, 48 and for FGF1 and FGF7 in OSEs. 49 Moreover, Steele et al. showed that ligands to FGFR2IIIb influenced a range of phenotypes important in the neoplastic growth of epithelial ovarian carcinoma cells. 49, 50 Autocrine FGF7 and paracrine FGF10 signaling loops may be involved in the increased epithelial differentiation during malignant transformation. Taken together, upregulated FGFR2 expression may lead to excessive FGFR2 signaling and could potentially be involved in the carcinogenesis of endometriomas.
Conclusion
The biological plausibility at the basis of the idea that endometriosis may be the precursor of ovarian cancer is not well validated. However, clinicians should carefully observe acute growth and mural nodules of endometriomas to identify subsets of women at increased risk of ovarian cancer. FGFR2 may be a good target for therapeutic intervention for the carcinogenetic progression of endometriosis. Based on previous findings and our own studies, additional studies need to be conducted if we hope to develop better prevention, screening and treatment approaches for malignant transformation of endometriosis.
